Cue biopharma announces upcoming scientific presentations at the society for immunotherapy of cancer's (sitc) 39th annual meeting

Boston, oct. 04, 2024 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific t cells, today announced it will deliver an oral and a poster presentation on the company's immuno-stat™ clinical assets cue-101 and cue-102, representative of the cue-100 series, at the society for immunotherapy of cancer's 39th annual meeting (sitc 2024). the conference will be held in houston, texas, on november 6-10, 2024.
CUE Ratings Summary
CUE Quant Ranking